Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs
by
Mettu, Vijaya Saradhi
, Slusher, Barbara S.
, Alt, Jesse
, Tenora, Lukáš
, Ranjit, Arina
, Rais, Rana
, Pal, Arindom
, Lee, Chae Bin
in
Amino acids
/ Analysis
/ Bioavailability
/ Brain research
/ Chromatography
/ dog pharmacokinetics
/ Dogs
/ DPTIP
/ Drug dosages
/ Enzymes
/ Evaluation
/ Health aspects
/ Metabolism
/ mice pharmacokinetics
/ nSMase2
/ oral bioavailability
/ Pharmacokinetics
/ Physiology
/ Plasma
/ Plasma physics
/ Polyethylene glycol
/ prodrug
/ Sensors
2025
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs
by
Mettu, Vijaya Saradhi
, Slusher, Barbara S.
, Alt, Jesse
, Tenora, Lukáš
, Ranjit, Arina
, Rais, Rana
, Pal, Arindom
, Lee, Chae Bin
in
Amino acids
/ Analysis
/ Bioavailability
/ Brain research
/ Chromatography
/ dog pharmacokinetics
/ Dogs
/ DPTIP
/ Drug dosages
/ Enzymes
/ Evaluation
/ Health aspects
/ Metabolism
/ mice pharmacokinetics
/ nSMase2
/ oral bioavailability
/ Pharmacokinetics
/ Physiology
/ Plasma
/ Plasma physics
/ Polyethylene glycol
/ prodrug
/ Sensors
2025
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs
by
Mettu, Vijaya Saradhi
, Slusher, Barbara S.
, Alt, Jesse
, Tenora, Lukáš
, Ranjit, Arina
, Rais, Rana
, Pal, Arindom
, Lee, Chae Bin
in
Amino acids
/ Analysis
/ Bioavailability
/ Brain research
/ Chromatography
/ dog pharmacokinetics
/ Dogs
/ DPTIP
/ Drug dosages
/ Enzymes
/ Evaluation
/ Health aspects
/ Metabolism
/ mice pharmacokinetics
/ nSMase2
/ oral bioavailability
/ Pharmacokinetics
/ Physiology
/ Plasma
/ Plasma physics
/ Polyethylene glycol
/ prodrug
/ Sensors
2025
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs
Journal Article
Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs
2025
Request Book From Autostore
and Choose the Collection Method
Overview
Background: Extracellular vesicles (EVs) can carry pathological cargo, contributing to disease progression. The enzyme neutral sphingomyelinase 2 (nSMase2) plays a critical role in EV biogenesis, making it a promising therapeutic target. Our lab previously identified a potent and selective inhibitor of nSMase2, named DPTIP (IC50 = 30 nM). Although promising, DPTIP exhibits poor pharmacokinetics (PKs) with a low oral bioavailability (%F < 5), and a short half-life (t1/2 ≤ 0.5 h). To address these limitations, we previously developed DPTIP prodrugs by masking its phenolic hydroxyl group, demonstrating improved plasma exposure in mice. Recognizing that species-specific metabolic differences can influence prodrug PK, we expanded our studies to evaluate selected prodrugs in both mice and dogs. Methods: The scaleup of selected prodrugs was completed and two additional valine- ester based prodrugs were synthesized. Mice were dosed prodrugs via peroral route (10 mg/kg equivalent). For dog studies DPTIP was dosed via intravenous (1 mg/kg) or peroral route (2 mg/kg) and prodrugs were given peroral at a dose 2 mg/kg DPTIP equivalent. Plasma samples were collected at predetermined points and analyzed using developed LC/MS-MS methods. Results: In mice, several of the tested prodrugs showed similar or improved plasma exposures compared to DPTIP. However, in dog studies, the double valine ester prodrug 9, showed significant improvement with an almost two-fold increase in DPTIP plasma exposure (AUC0–t = 1352 vs. 701 pmol·h/mL), enhancing oral bioavailability from 8.9% to 17.3%. Conclusions: These findings identify prodrug 9 as a promising candidate for further evaluation and underscore the critical role of species-specific differences in prodrug PKs.
This website uses cookies to ensure you get the best experience on our website.